講演情報
[F1-21]Utilization of a Novel Mast Cell Line, “Cell-line of Serosa-Infiltrated Mast Cell for Versatile Analysis#1 (cSIMVA1),” for Vaccine Modality Validation
*Yuqing WU1,2, Haruki SASA1,2, NAREN TONGLEGA1,2, Zhongwei Zhang1,2, Mariko KITAJIMA3, Hayato ISHIKAWA3, Hiroshi KIYONO1,2,4, Yosuke KURASHIMA1,2,4 (1. Department of Innovative Medicine, Graduate School of Medicine, Institute for Advanced Academic Research/ Research Institute of Disaster Medicine, Chiba University, Chiba, Japan. (Japan), 2. Chiba University Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba, Japan. (Japan), 3. Laboratory of Middle Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Chiba University (Japan), 4. Division of Comparative Pathology and Medicine, Chiba University-University of California San Diego Center for Mucosal Immunology, Allergy and Vaccine (cMAV), School of Medicine, San Diego, CA, USA. (United States of America))
